SUBSCRIBE

cystic fibrosis

FDA approves new drug for cystic fibrosis

On July 2, the U.S. Food and Drug Administration (FDA) approved Orkambi (lumacaftor 200 mg/ivacaftor 125 mg) for the treatment of cystic fibrosis (CF) in patients 12 years…

FDA expands approved use of Kalydeco for CF

On May 17, the U.S. Food and Drug Administration (FDA) expanded the approved use of Kalydeco (ivacaftor) for treating cystic fibrosis (CF), tripling the number of rage gene…

New treatment for cystic fibrosis

The U.S. Food and Drug Administration has approved a new “breakthrough therapy” for cystic fibrosis (CF) in late October 2019. (more…)

The changing face of cystic fibrosis

It’s no longer a childhood illness. Takeaways: The Cystic Fibrosis Foundation Patient Data Registry shows that more than 54% of people with cystic fibrosis live 18 years and…

Reader Survey

Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.

Survey
cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Test Your Knowledge

Which of the following statements accurately describes hypertrophic cardiomyopathy (HCM)?